Elicio Therapeutics, Inc.

Elicio Therapeutics is a clinical-stage biotechnology company developing amphiphile-based immunotherapies for cancer and other diseases — with lead candidate ELI-002 (KRAS-mutation-targeted therapeutic vaccine) in pancreatic ductal adenocarcinoma and other KRAS-driven tumors. Down 64% YTD and 71% over 12 months as continued cash burn plus dilutive-financing dynamics compressed the tape — the July 2 $15M registered-direct offering plus Pomerantz Law investigation frame the setup into the August 6 Q2 print.

Where the setup sits:

• Q1 was pre-commercial: no revenue with EPS negative $0.65 versus negative $0.49 consensus (33% miss) — P&L is runway management and the miss reflects deeper spending than expected.
• The July 2 Securities Purchase Agreement for 4.38M shares at $3.43 raising $15M gross is the substantive dilutive event — Titan Partners and B. Riley acted as placement agents.
• Multiple Pomerantz Law Firm investigation disclosures signal plaintiff-bar attention to recent price-and-disclosure history — typically fishing expeditions but the clustering warrants weighting.
• Position at 1% of 52-week range with tape 56% below the 50-day and 68% below the 200-day — fully capitulated; any positive catalyst has torque but base case remains continued compression.

August 6 is the pivot: a Q2 print that at minimum narrows the loss gap versus negative $0.53 consensus plus firm 2027 ELI-002 pancreatic-clinical-trial-progression commentary is what breaks the current selling; another material EPS miss or a fresh dilutive-raise signal and the -64% YTD extends toward the lows as the going-concern math tightens.